Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis

Canadian Journal of Neurological Sciences

Volumn 39, Issue 6, 2012, Pages 813-820

  Wu, Aimin ^a   Zhong, Xiaonan ^a   Wang, Honghao ^a   Xu, Wen ^a   Cheng, Chen ^a   Dai, Yongqiang ^a   Bao, Jian ^a   Qiu, Wei ^a   Lu, Zhengqi ^a   Hu, Xueqiang ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT; INTERLEUKIN 21;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICAL ARTICLE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84867973340     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100015663     Document Type: Article

References (38)

1. Matà S, lolli F. Neuromyelitis optica: An update. J Neurol Sci. 2011;303(1-2):13-21.
2. Fletcher JM, lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin exp Immunol. 2010;162(1):1-11.
3. li Y, Wang H, long Y, et al. Increased memory Th17cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2011;234(1-2):155-60.
4. link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin lab Invest. 1977;37(5):397-401.
5. Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol. 2000;47(6): 694-706.
6. lennon v.A, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. lancet. 2004;364(9451):2106-12.
7. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13(1):128-32.
8. Bakker J, Metz l. Devic's neuromyelitis optica treated with intravenous gamma globulin (IvIG). Can J Neurol Sci. 2004;31 (2):265-7.
9. Cree BA, lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64 (7):1270-2.
10. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225-30.
11. Pellkofer Hl, Krumbholz M, Berthele A, et al. long-term followup of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-5.
12. Ozaki K, Kikly K, Michalovich D, et al. Cloning of a type I cytokine receptor most related to the Il-2 receptor beta chain. Proc Natl Acad Sci USA. 2000;97(21):11439-44.
13. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57-63.
14. Spolski R, leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008:26:57-79.
15. Monteleone G, Caruso R, Fina D, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut. 2006;55(12):1774-80.
16. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci. 2009;30(8):441-7.
17. Deenick eK, Tangye SG. Autoimmunity: Il-21: A new player in Th17-cell differentiation. Immunol Cell Biol. 2007;85(7):503-5.
18. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 (Il-21)- mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev. 2009;20(2):185-91.
19. Konforte D, Simard N, Paige CJ. Il-21: An executor of B cell fate. J Immunol 2009;182(4):1781-7.
20. ettinger R, Kuchen S, lipsky Pe. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis. 2008;67 Suppl 3:iii83-6.
21. ettinger R, Kuchen S, lipsky Pe. The role of Il-21 inregulating Bcell functionin health and disease. Immunol Rev. 2008;223: 60-86.
22. Wang HH, Dai Yq, qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18(10):1313-7.
23. Wingerchuk DM, lennon vA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10): 1485-9.
24. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
25. vollmer Tl, liu R, Price M, et al. Differential effects of Il-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol. 2005;174(5):2696-701.
26. Chen M, Chen G, Nie H, et al. Regulatory effects of IFN-beta on production of osteopontin and Il-17 by CD4+ T Cells in MS. eur J Immunol. 2009;39(9):2525-36.
27. Zhang X, Tao Y, Troiani l, et al. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011;187(6):3431-7.
28. Xie l, li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of Il-17 production. Int Immunopharmacol. 2009;9(5):575-81.
29. Andersson A, Isaksson M, Wefer J, et al. Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis. PloS One. 2008;3(11):e3682.
30. Kwok SK, Cho Ml, Park MK, et al. Interleukin-21 promotes osteoclasto genesis in rheumatoid arthritis in humans and mice. Arthritis Rheum. 2012;64(3):740-51
31. Kang KY, Kim HO, Kwok SK, et al. Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: Increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther. 2011;13(5):R179.
32. Tüzün e, Kürtüncü M, Türkoǧlu R, et al. enhanced complement consumption in neuromyelitis optica and Behçet's disease patients. J Neuroimmunol. 2011;233(1-2):211-5.
33. Doi H, Matsushita T, Isobe N, et al. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler. 2009;15(3):304-10.
34. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630-43.
35. Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: Aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4(4): 202-14.
36. Fedetz M, Ndagire D, Fernandez O, et al. Multiple sclerosis association study with the TeNR-Il2-Il21 region in a Spanish population. Tissue Antigens. 2009;74(3):244-7.
37. lindén M, Nohra R, Sundqvist e, et al. No evidence of Il21 association with multiple sclerosis in a Swedish population. Tissue Antigens. 2011;78(4):271-4.
38. Tzartos JS, Craner MJ, Friese MA, et al. Il-21 and Il-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol. 2011;178(2):794-802.